Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax Pharma has the GF Score of 39, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Parmax Pharma
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Parmax Pharma (BOM:540359) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Parmax Pharma GF Score Related Terms
BOM:540359 vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's GF Score distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's GF Score falls into.
Parmax Pharma (BOM:540359) has a GF Score of 39 as of Jul. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Parmax Pharma and its competitors. This is 24% below median its historical median of 51.00. Over the past decade, Parmax Pharma's GF Score has ranged from 6.00 to 76.00.
Is Parmax Pharma's GF Score too high?
Parmax Pharma's current GF Score of 39 is 24% below median its 10-year median of 51.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 76.00. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's GF Score compare to ZTS and UTHR?
Parmax Pharma's GF Score of 39 can be compared against companies in the Drug Manufacturers industry. Historically, Parmax Pharma's own GF Score has ranged from 6.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Parmax Pharma and its competitors. Parmax Pharma's current GF Score is 39, which is 24% below median its own 10-year median of 51.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.55, compared to a current price of ₹104.97 — trading 310.8% above its estimated fair value. The current GF Score is 39, which is 24% below median its 10-year median of 51.00. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current GF Score is 39 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹104.97 is trading 310.8% above its estimated GF Value™ of ₹25.55.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
GF Score: 39 (24% below median its 10-year median of 51.00)
GF Value™: ₹25.55 vs. price of ₹104.97 (310.8% above fair value)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
